ArticleMolecules (Basel, Switzerland)2019
Synthesis, Characterization of Liposomes Modified with Biosurfactant MEL-A Loading Betulinic Acid and Its Anticancer Effect in HepG2 Cell.
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 48 citations in OpenAlex.
- Insights into the Recent Breakthroughs in Nanotechnological Outlook of Pentacyclic Triterpenoids: An Updated Approach.Current pharmaceutical design · 2026Review
- Biosurfactants as next-generation antimicrobials: mechanistic insights and applications in antibiofilm strategies for combatting antimicrobial resistance.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Vesicular Carriers for Phytochemical Delivery: A Comprehensive Review of Techniques and Applications.Pharmaceutics · 2025Review
- A Review on Nanotechnologically Derived Phytomedicines for the Treatment of Hepatocellular Carcinoma: Recent Advances in Molecular Mechanism and Drug Targeting.Current drug targets · 2025Review
- Cytotoxic Potential of Betulinic Acid Fatty Esters and Their Liposomal Formulations: Targeting Breast, Colon, and Lung Cancer Cell Lines.Molecules (Basel, Switzerland) · 2024Article
- Application of Biosurfactants in Medical Sciences.Molecules (Basel, Switzerland) · 2024Review
- Drug Delivery Systems of Betulin and Its Derivatives: An Overview.Biomedicines · 2024Review
- A novel strategy for partial purification of alkane hydroxylase from P. chrysogenum SNP5 through reconstituting its native membrane into liposome.Scientific reports · 2024Article
- Advancements in Betulinic Acid-Loaded Nanoformulations for Enhanced Anti-Tumor Therapy.International journal of nanomedicine · 2024Review
- Pentacyclic Triterpenoid Phytochemicals with Anticancer Activity: Updated Studies on Mechanisms and Targeted Delivery.International journal of molecular sciences · 2023Review
- Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma.Pharmaceutics · 2023Review
- Recent updates on nano-phyto-formulations based therapeutic intervention for cancer treatment.Oncology research · 2023Review
- Phytochemical Compounds and Nanoparticles as Phytochemical Delivery Systems for Alzheimer's Disease Management.Molecules (Basel, Switzerland) · 2022Review
- Triterpenoids as Reactive Oxygen Species Modulators of Cell Fate.Chemical research in toxicology · 2022Review
- The Optimized Delivery of Triterpenes by Liposomal Nanoformulations: Overcoming the Challenges.International journal of molecular sciences · 2022Review
- Phytofabricated Nanoparticle Formulation for Cancer Treatment: A Comprehensive Review.Current drug metabolism · 2022Review
- Anti-Inflammatory and Anticancer Properties of Birch Bark-Derived Betulin: Recent Developments.Plants (Basel, Switzerland) · 2021Review
- Nanoformulations for Delivery of Pentacyclic Triterpenoids in Anticancer Therapies.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
As a novel natural compound delivery system, liposomes are capable of incorporating lipophilic bioactive compounds with enhanced compound solubility, stability and bioavailability, and have been successfully translated into real-time clinical applications. To construct the soy phosphatidylcholine (SPC)-cholesterol (Chol) liposome system, the optimal formulation was investigated as 3:1 of SPC to Chol, 10% mannosylerythritol lipid-A (MEL-A) and 1% betulinic acid. Results show that liposomes with or without betulinic acid or MEL-A are able to inhibit the proliferation of HepG2 cells with a dose-effect relation remarkably. In addition, the modification of MEL-A in liposomes can significantly promote cell apoptosis and strengthen the destruction of mitochondrial membrane potential in HepG2 cells. Liposomes containing MEL-A and betulinic acid have exhibited excellent anticancer activity, which provide factual basis for the development of MEL-A in the anti-cancer applications. These results provide a design thought to develop delivery liposome systems carrying betulinic acid with enhanced functional and pharmaceutical attributes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.